Sign in

Research summary ·

Treatment of children and young adults with a Fontan circulation and cardiovascular dysfunction. 2026 Consensus Statement from the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AHA, AEPC, EACTS, ISACHD, ISHLT and PICS.

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This is a guideline led by the EPPVDN network. An expert group from many countries and fields wrote it. It is about children and young adults who had the Fontan operation. This surgery helps many people born with single ventricle heart disease live long. But the Fontan blood flow puts a lifelong strain on the heart and vessels. The group read past research and agreed on advice for doctors. They graded how strong the advice and its evidence are.

What they found

The abstract gives advice, not study results. The guideline covers how doctors check the heart and blood vessels. It covers disease of the lung blood vessels and drugs that widen them. It deals with blocks in the Fontan path and problems in veins and arteries. It also covers extra side vessels and problems with the lymph system. It covers weak heart muscle, heart failure drugs, and the risk of clots. Drugs that stop clots are also part of it. The advice is set out in graded tables and a flow chart.

What it means for patients

The guideline says doctors can shape care around each person's type of problem. It says blood flow and pressure measures can guide treatment choices. Care may include drugs, surgery, or procedures done through thin tubes. These options are adapted to the Fontan blood flow. The tables and chart aim to help doctors make choices.

Why it is not certain yet

There is little research done just in people with a Fontan circulation. Because of this, much of the advice is based on expert opinion. The authors list gaps in what is known today. They call for shared research to help people living with a Fontan circulation.

Source

Treatment of children and young adults with a Fontan circulation and cardiovascular dysfunction. 2026 Consensus Statement from the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AHA, AEPC, EACTS, ISACHD, ISHLT and PICS.

PubMed · PMID 43018530

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Congenital heart disease publications